Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T17:57:05.418Z.
Calculation as of: 2026-10-06T17:57:05.418Z.
Quote observation: 2026-10-06T17:51:30.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2fde06f259e28fcaf0a0d51df993d991938700e907f86078bced96cac1655d96
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Market Cap
$7.08M
Operating Cash Flow Yield
N/A
TTM Avg
0.21%
3Y Avg
0.21%
5Y Avg
0.21%
Market Cap
$7.08M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.13M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.13M
Operating Cash Flow Yield
N/A
TTM Avg
19.02%
3Y Avg
17.20%
5Y Avg
17.20%
Market Cap
$6.94M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.90M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.25M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| KALA BIO, Inc. (KALA) | $7.07M | N/A | N/A | N/A | N/A |
| Exicure, Inc. (XCUR)vs › | $7.08M | N/A | 0.21% | 0.21% | 0.21% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | N/A | N/A | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.13M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.13M | N/A | 19.02% | 17.20% | 17.20% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.94M | N/A | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.21M | N/A | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $6.90M | N/A | N/A | N/A | N/A |
| Skye Bioscience, Inc. (SKYE)vs › | $7.25M | N/A | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A | 0.00% | 0.00% | 0.00% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
